Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score)

Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer after Chemoradiotherapy

“…The nadir value of CA19-9 level after treatment was utilized for the estimation of CA19-9 decrease. Hence, CA19-9 response was strati ed as follows: CA19-9 levels ≥ 74 U/ml with response vs. CA19-9 levels ≥ 74 U/ml with no response (including CA19-9 levels within the normal range before treatment while increasing after treatment) vs. CA19-9 levels < 74 U/ml all along before and after treatment, which have been used in our previous studies [13][14][15]. Furthermore, it was reported that patients with a CA19-9 level less than 200 U/ml had major response when they received neoadjuvant therapy.…”

“…Therefore, the baseline level of CA19-9 before treatment was strati ed as: <200 U/ml and ≥ 200 U/ml. Besides, in our previous studies, it was demonstrated that BED 10 (biological effective dose, α/β = 10) ≥ 60Gy correlated with overall survival (OS) in patients with pancreatic cancer [13,14,17,18]. Therefore, BED 10 was strati ed into two groups for analysis: BED 10 ≥ 60Gy and BED 10 < 60Gy.…”

“…Irradiation of pancreatic cancer was performed with SBRT via CyberKnife® (Accuray Incorporated, Sunnyvale, CA), as described previously [13][14][15]18]. Three gold ducials within or adjacent to the pancreatic tumor were preferable.…”

Update on current pancreatic treatments: from molecular pathways to treatment

“…Moreover; It was observed that stereotactic body radiotherapy and anti-CD40 are so effective at augmenting T cell priming, that memory CD8 T cell responded that both tumor and self-antigens were induced, resulting in vitiligo in long-term survivors 67. In another study the SCAD score was evaluated as a method to identify individuals benefiting from re-stereotactic body radiotherapy 68. PARP inhibitors can be used in combination with chemo- or radiotherapy or as single agents alone 69.…”

Biologically effective doses of 60-70Gy vs. &gt;70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a phase III study

“…However, there was limited evidence about the correlation between high doses and better outcomes in the case of radiotherapy of pancreatic cancer, while it had been proven that high doses may be predictive of superior survival regarding lung cancer and liver cancer. Our previous studies have clari ed that biologically effective dose (BED, α/β = 10) ≥ 60Gy may be associated with better prognosis [5,6].…”